Amgen reported strong quarterly results, surpassing expectations and raising full-year guidance. The company demonstrated robust performance from key products like Enbrel and made significant progress in its pipeline, notably advancing AMG 785 and AMG 145 into Phase III trials. Strategic acquisitions and a commitment to shareholder returns further enhance positive sentiment, suggesting the stock will rally in the short term.

[2]